Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 30 min ago
PreprintCC BY-NC-NDbioRxiv

Glucosylceramide synthase is required for C6-ceramide nanoliposome-induced organelle stress and cell death

  1. 1University of Virginia

Abstract

Sphingolipids are bioactive lipids that regulate key signaling pathways both directly as ligands and through membrane re-organization. Ceramide sits at the center of this network and is considered pro-death in many contexts, making ceramide accumulation an attractive therapeutic strategy. Given the wide-ranging regulation of cellular responses this network exerts, better understanding ceramide metabolism may promote therapeutic efficacy of sphingolipid-based therapeutics. Ceramide glycosylation, catalyzed by glucosylceramide synthase (GCS; UGCG), is in turn widely regarded as a detoxification route thus limiting efficacy of ceramide- based therapeutics. Here we show the opposite. Delivery of short-chain C6-ceramide via a ceramide nanoliposome (CNL) induced organelle stress and cell death in chronic lymphocytic leukemia (CLL) via the accumulation of glycosphingolipids (GSLs), rather than through ceramide itself. Pharmacologic and genetic blockade of GCS protected B-cell leukemia, breast carcinoma, glioblastoma, lung adenocarcinoma, and non- malignant embryonic kidney cells from CNL-induced death. Conversely, exogenous C8-glucosylceramide was sufficient to kill cells that cannot degrade it. We show that GSL accumulation drives an ordered organelle response beginning with lysosomal deacidification, endoplasmic reticulum stress, followed by mitochondrial respiratory capacity decline, each attenuated by inhibition of GSL synthesis. These effects were accompanied by MLKL phosphorylation, increased activity of the stress sensor JNK and CHOP induction, with JNK inhibition partially protecting from death. These findings invert the prevailing view of ceramide glycosylation as a resistance mechanism and identify glycosphingolipid flux as a required effector arm of ceramide-directed therapy.

Related

  1. Dietary Glucosylceramide Attenuates Irinotecan-Induced Jejunal Inflammation in Mice without Altering Apoptotic Signaling in the Jejunum
    Momoka Ota, Shinji Yamashita, Yuki Yokota +2
    Journal of Oleo SciencePeer-reviewedCC BYFull textGeneral medicineJ-STAGE
  2. Plasma ceramide ratios define metabolic–inflammatory associations with cognitive impairment in Parkinson’s disease
    Nuan Wang, Guoqing Zhang, Chang Li +7
    npj Parkinson's DiseasePeer-reviewedCC BYFull textNeurologyDOAJ
  3. Ceramide Metabolic Pathways and Their Regulation in Adolescent Acne Vulgaris
    Yvwei Gou, Hua Wu, Xingyi Wu +4
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  4. Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissue.
    Annalise Schweickart, Richa Batra, Kevin Huynh +17
    Alzheimer's & dementia : the journal of the Alzheimer's AssociationPeer-reviewedCC BY-NCFull textPhysiologyEurope PMC
  5. Effect of a Ceramide NP-Containing Moisturizer on Skin Barrier Function in Adults with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Study
    Chao-ying Gu, Jia-yi Ying, Hui-bin Yin +2
    Skin Pharmacology and PhysiologyPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
BibTeX
@misc{vass2026glucosylceramide,
  title = {{Glucosylceramide synthase is required for C6-ceramide nanoliposome-induced organelle stress and cell death}},
  author = {L. R. Vass and E. W. Smith and J. M. Cavanaugh and S. L. Johnson and A. Sabzevari and P. Costa-Pinheiro and J. J. P. Shaw and T. P. Loughran and T. E. Fox},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.21.753214},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.21.753214v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Glucosylceramide synthase is required for C6-ceramide nanoliposome-induced organelle stress and cell death
AU  - L. R. Vass
AU  - E. W. Smith
AU  - J. M. Cavanaugh
AU  - S. L. Johnson
AU  - A. Sabzevari
AU  - P. Costa-Pinheiro
AU  - J. J. P. Shaw
AU  - T. P. Loughran
AU  - T. E. Fox
PY  - 2026
DA  - 2026/09/21
PB  - bioRxiv
DO  - 10.64898/2026.09.21.753214
UR  - https://www.biorxiv.org/content/10.64898/2026.09.21.753214v1
AB  - Sphingolipids are bioactive lipids that regulate key signaling pathways both directly as ligands and through membrane re-organization. Ceramide sits at the center of this network and is considered pro-death in many contexts, making ceramide accumulation an attractive therapeutic strategy. Given the wide-ranging regulation of cellular responses this network exerts, better understanding ceramide metabolism may promote therapeutic efficacy of sphingolipid-based therapeutics. Ceramide glycosylation, catalyzed by glucosylceramide synthase (GCS; UGCG), is in turn widely regarded as a detoxification route thus limiting efficacy of ceramide- based therapeutics. Here we show the opposite. Delivery of short-chain C6-ceramide via a ceramide nanoliposome (CNL) induced organelle stress and cell death in chronic lymphocytic leukemia (CLL) via the accumulation of glycosphingolipids (GSLs), rather than through ceramide itself. Pharmacologic and genetic blockade of GCS protected B-cell leukemia, breast carcinoma, glioblastoma, lung adenocarcinoma, and non- malignant embryonic kidney cells from CNL-induced death. Conversely, exogenous C8-glucosylceramide was sufficient to kill cells that cannot degrade it. We show that GSL accumulation drives an ordered organelle response beginning with lysosomal deacidification, endoplasmic reticulum stress, followed by mitochondrial respiratory capacity decline, each attenuated by inhibition of GSL synthesis. These effects were accompanied by MLKL phosphorylation, increased activity of the stress sensor JNK and CHOP induction, with JNK inhibition partially protecting from death. These findings invert the prevailing view of ceramide glycosylation as a resistance mechanism and identify glycosphingolipid flux as a required effector arm of ceramide-directed therapy.
ER  -